Are Viyash Scientific Ltd latest results good or bad?

Viyash Scientific Ltd's latest financial results for Q4 FY26 reveal significant operational advancements, showcasing a remarkable turnaround from previous loss-making periods. The company reported net sales of ₹919.96 crores, reflecting a year-on-year growth of 129.02%, driven by strong demand in both Active Pharmaceutical Ingredients (APIs) and finished dosage formulations within the animal health segment. This performance marks an all-time high for the company, indicating robust market traction. Net profit for the quarter reached ₹52.11 crores, a substantial increase of 459.12% year-on-year. This surge in profitability is complemented by an operating margin of 20.03%, which has been sustained above 20% for three consecutive quarters—an improvement from the single-digit margins observed in early FY25. The company's operational efficiencies and a favorable product mix have contributed to this margin expansion. Despite these positive trends, Viyash Scientific faces challenges, including a significant rise in its effective tax rate to 47%, which raises questions about the sustainability of its reported profitability. The company also continues to grapple with historical profitability metrics, as indicated by its average Return on Capital Employed (ROCE) of 6.30% over the past five years, although the latest figure for FY26 shows improvement at 18.12%. Furthermore, the company's balance sheet reflects gradual improvement, with shareholder funds increasing to ₹704.47 crores. However, long-term debt has risen to ₹273.88 crores, indicating ongoing investments in capacity expansion. The current liabilities have decreased, suggesting better working capital management. Overall, Viyash Scientific's recent results illustrate a significant operational turnaround, with the company experiencing an adjustment in its evaluation amidst a backdrop of improving financial metrics. Investors should remain attentive to the sustainability of these trends, particularly in light of the elevated tax burden and historical profitability concerns.